Company news

AtaiBeckley Inc. news in 2025

AtaiBeckley Inc.'s news releases, calls and decks from 2025, newest first.

View company

AtaiBeckley Completes Redomiciliation to the United States

December 30, 2025

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

December 23, 2025

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio

December 10, 2025

Enhanced Fortifies Executive Leadership Team & Board of Directors

November 19, 2025

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

November 12, 2025

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 11, 2025

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

November 9, 2025

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies

November 4, 2025

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

October 19, 2025

atai Life Sciences Announces Proposed Public Offering of Common Shares

October 15, 2025

atai Life Sciences Announces Pricing of Public Offering of Common Shares

October 15, 2025

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

October 15, 2025

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

September 22, 2025

atai Life Sciences Awarded Grant from the National Institutes of Health

September 17, 2025

atai Life Sciences to Participate in September Investor Conferences

August 27, 2025

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 13, 2025

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

July 24, 2025

atai Life Sciences Announces $50 Million Private Placement Financing

June 30, 2025

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

June 30, 2025

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

June 1, 2025

atai Life Sciences to Participate in Upcoming Investor Conferences

May 28, 2025

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

May 19, 2025

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 13, 2025

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

May 12, 2025

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

March 16, 2025

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

March 10, 2025

atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

March 4, 2025

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

February 23, 2025

atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

January 27, 2025

atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

January 9, 2025

Decks in 2025